CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

As of September 30, 2024, the Company had cash of approximately $7.0 million. Subsequent to the quarter end, the Company closed a $3.0 million ...

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 Company strengthens ...

Investor Relations - CNS Pharmaceuticals

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results. 15 November, 2024. Primary analysis data in potentially pivotal GBM study with lead program, ...

CNS Pharma on X: "CNS Pharmaceuticals Reports Third Quarter ...

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results https://t.co/LSAwGIXOef $CNSP #GBM #BrainTumors #GlioblastomaMultiforme.

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results $CNSP https://t.co/KvO7swP3Bq.

CNS Pharmaceuticals | Home

Latest News. CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results. Read More of CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results ...

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial ...

Net product sales of DAYBUE were $251.7 million and $90.1 million for the nine months ended September 30, 2024 and 2023, respectively. The increase in net ...

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial ...

STATEMENTS OF OPERATIONS DATA: 2024 ; Revenues, $, — ; Operating expenses: Research and development ; Research and development, 61,905 ...

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial ...

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update · Third quarter 2024 global net product sales of ...

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results · Comments Section · Community Info Section · More posts you may like.

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial ...

For the nine months ended September 30, 2024, R&D expenses were $82.1 million, compared to $60.7 million for the nine months ended September 30, 2023, an ...

Amneal Reports Third Quarter 2024 Financial Results

2024 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third ...

Avadel Pharmaceuticals Provides Corporate Update and Reports ...

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results · $3.8 million in the quarter ended September ...

Intra-Cellular Therapies Reports Third Quarter 2024 Financial ...

Net loss for the third quarter of 2024 was $26.3 million compared to a net loss of $24.3 million for the same period in 2023. Cost of product sales was $15.3 ...

Chimerix Reports Third Quarter 2024 Financial Results and ...

Research and development expenses increased to $19.6 million for the third quarter of 2024 compared to $17.4 million for the same period in 2023. General and ...

Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results

Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results ; Product revenue, net, $, 17,676 ; Licensing and other revenue, 4,380 ; Total ...

Earnings - BioSpace

November 15, 2024. ·. 10 min read. Press Releases · CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results. November 15, 2024. ·. 6 min read. Press ...

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Product sales and royalty revenue were $9.8 million for the third quarter of 2024, an increase of 40% compared to $7.0 million in the prior year ...

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

SG&A Expenses: Selling, general and administrative expenses were $17.8 million for the three months ended September 30, 2024, compared to $48.7 ...

Untitled